The private label CBD gummies market is poised for significant expansion, with Future Market Insights (FMI) forecasting growth from USD 646.2 million in 2026 to USD 1,382.2 million by 2036, at a compound annual growth rate (CAGR) of 7.9%. This growth is fueled by wellness brands increasingly turning to outsourced manufacturing to reduce capital investment and accelerate time-to-market for CBD edible products.
According to FMI, the market was valued at USD 598.9 million in 2025. The shift toward white-label production models is a key driver, as they lower launch costs and shorten commercialization timelines. White label gummies are expected to dominate the service model segment, capturing 46.2% of global demand in 2026. Their appeal lies in ready-made formulations and established manufacturing processes, allowing brands to focus on marketing and customer acquisition.
Broad-spectrum CBD gummies are leading the spectrum segment with a 42.8% market share in 2026, driven by consumer preference for THC-free products that retain multiple cannabinoids. This positioning improves retail acceptance and simplifies regulatory compliance, as retailers and regulators emphasize batch testing, ingredient traceability, and labeling accuracy.
Brand websites are the leading sales channel, accounting for 39.6% of demand in 2026. Direct-to-consumer platforms enable brands to educate customers on dosage, lab testing, and ingredient sourcing, while supporting subscription models and repeat purchases. The United States is the fastest-growing market, with a projected CAGR of 8.5% through 2036, supported by a mature CBD ecosystem and strong direct-to-consumer infrastructure.
Key market players include CBD Nationwide, Extract Labs, cbdMD, Inc., Charlotte's Web Holdings, Inc., CV Sciences, Inc., Medterra CBD LLC, British Cannabis, Cannaray Limited, MediPharm Labs Corp., and Little Green Pharma Ltd. These companies compete on formulation expertise, manufacturing scalability, compliance support, and private label services.
Despite strong growth prospects, regulatory complexity remains a restraint, as differences in CBD regulations across countries can delay commercialization and increase costs. However, trends such as customized formulations for sleep and relaxation, third-party lab testing, sustainable packaging, and subscription-based models are expected to drive continued expansion.
For detailed market forecasts and competitive benchmarking, access the full report at https://www.futuremarketinsights.com/reports/sample/rep-gb-33370 and the complete PDF at https://www.futuremarketinsights.com/reports/brochure/rep-gb-33370.
